Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $74,800.00 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Jay M. Moyes sold 22,000 shares of Puma Biotechnology stock in a transaction on Friday, June 13th. The shares were sold at an average price of $3.40, for a total value of $74,800.00. Following the sale, the director now directly owns 53,322 shares of the company's stock, valued at approximately $181,294.80. The trade was a 29.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Puma Biotechnology Price Performance

PBYI traded down $0.21 on Friday, reaching $3.19. The stock had a trading volume of 314,744 shares, compared to its average volume of 443,070. The company has a market capitalization of $158.32 million, a price-to-earnings ratio of 4.14 and a beta of 1.29. Puma Biotechnology, Inc. has a fifty-two week low of $2.23 and a fifty-two week high of $4.13. The firm has a 50-day moving average of $3.22 and a 200-day moving average of $3.12. The company has a current ratio of 1.53, a quick ratio of 1.43 and a debt-to-equity ratio of 0.11.

Hedge Funds Weigh In On Puma Biotechnology

Several hedge funds have recently modified their holdings of the company. Strs Ohio purchased a new stake in shares of Puma Biotechnology in the first quarter worth about $420,000. Acadian Asset Management LLC boosted its position in Puma Biotechnology by 1.8% during the 1st quarter. Acadian Asset Management LLC now owns 2,008,146 shares of the biopharmaceutical company's stock valued at $5,940,000 after acquiring an additional 36,018 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Puma Biotechnology in the 1st quarter worth about $66,000. AQR Capital Management LLC increased its position in Puma Biotechnology by 366.5% during the 1st quarter. AQR Capital Management LLC now owns 50,458 shares of the biopharmaceutical company's stock valued at $149,000 after buying an additional 39,641 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in Puma Biotechnology by 3.8% in the first quarter. Royal Bank of Canada now owns 85,999 shares of the biopharmaceutical company's stock worth $254,000 after buying an additional 3,117 shares during the last quarter. Institutional investors own 61.29% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on PBYI. Wall Street Zen upgraded shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd. HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Puma Biotechnology in a report on Friday, February 28th.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.